CDKN2B-AS1 Genotype (rs10757278)

A stretch of DNA on chromosome 9, called 9p21.3, is one of the most replicated disease-linked regions in human genetics. The version you inherited is set at birth. It can shift your lifetime odds of coronary heart disease, primary open-angle glaucoma, and a few cancers, but the direction and size of risk depend on the exact variant.

This is a one-time genotype test. It reads one or more variants in the 9p21 region, usually from a buccal swab or another DNA sample. A positive result does not diagnose disease. A negative result does not clear you. It refines the starting risk you bring to prevention decisions.

Clinically, 9p21 is an emerging risk marker. The coronary signal is well repeated, but testing healthy people for 9p21 has not been shown to improve outcomes or add much to standard risk scores. That puts it below ApoB, blood pressure, smoking, and family history in day-to-day decisions.

What This Region Actually Does

CDKN2B-AS1, also called ANRIL, makes a long noncoding RNA. Long noncoding RNA helps control gene activity rather than serving as the recipe for a protein. In this region it can change the activity of nearby cell-growth brake genes, including CDKN2A and CDKN2B.

Those brake genes help stop cells from dividing when they shouldn't and help push worn-out cells into senescence. Senescence is cellular retirement: a cell is alive, but it no longer divides. That link to cell growth and aging is why 9p21 shows up in artery disease, glaucoma, and cancer studies.

Read The Exact Variant

9p21 is a region, not one universal switch. A SNP is a one-letter DNA spelling difference. A heart-risk SNP such as rs1333049 is not the same measurement as a glaucoma SNP or a cancer SNP in the same region.

Some of these variants travel together in European and East Asian ancestries, and less so in others. Read your report by variant name. If your report does not include the named SNP behind a study, don't import that study's risk estimate into your own result.

Coronary Heart Disease And Heart Attack

This is the strongest and most repeated finding at 9p21. Pooled analyses put the per-risk-allele increase in coronary heart disease at roughly 20 to 30%, with odds ratios generally in the 1.2 to 1.3 range across large meta-analyses. Allele-coding conventions differ between reports, so the same variant can appear as risk in one paper and protective in another depending on which allele is counted. A related variant, rs4977574 G, shows the same pattern, and in one Saudi cohort rs2891168 was reported to more than double the odds of coronary artery disease, an effect size larger than most other populations and worth reading with caution.

For people with type 1 diabetes, a 9p21 variant called rs1970112 raised coronary artery disease risk by about a third (odds ratio 1.32) and was strong enough to stand out across the whole genome, even after accounting for diabetic kidney disease.

If your report includes a coronary risk variant, your baseline heart-attack risk is higher than the same risk profile without that variant. It doesn't mean a heart attack is coming. It makes earlier ApoB and Lp(a) testing, tighter blood pressure control, and selective calcium scoring easier to justify. No trial has shown that 9p21-guided prevention beats prevention guided by the usual risk factors.

Glaucoma, Especially At Normal Pressure

9p21 is one of the more reliably replicated genetic signals for primary open-angle glaucoma in European and East Asian populations. What is unusual is the pattern. Several risk alleles are linked to normal-tension glaucoma and larger cup-to-disc ratios despite lower eye pressure. Eye pressure is only one part of glaucoma screening. If a report includes one of these glaucoma-linked variants, optic nerve imaging and visual field testing matter more than pressure alone.

Cup-to-disc ratio is one way eye doctors judge optic nerve damage. In a US study of nearly 3,000 people with primary open-angle glaucoma, nine of ten protective minor alleles at this region were tied to a smaller cup-to-disc ratio even though eye pressure ran slightly higher. The adverse allele studied did the opposite: it was linked to more optic nerve damage at lower pressure.

In African-ancestry cohorts, the same variants don't always behave the same way. One CDKN2B-AS1 variant was associated with primary open-angle glaucoma in African Americans and another with high-pressure glaucoma. No significant CDKN2B-AS1 signal was found in Ghanaian samples. If your ancestry is African, the glaucoma meaning of a European-derived SNP result is less certain.

Cancer Risk

Different variants at this region point to different cancer risks, sometimes in opposite directions. This is not one uniform cancer signal. It is a set of related findings, and most are not strong enough to drive cancer screening on their own.

• Pancreatic cancer: in a study of 14,666 cases and 221,897 controls, the T allele at rs1412832 raised pancreatic cancer odds by about 11%.
• Breast cancer: in one small study of 104 cases and 110 controls, the AA genotype at rs2383207 tripled the odds of breast cancer. Among women with breast cancer in that cohort, GG carriers had longer mean survival, about 20.6 months versus 15.8 months for AA. This is a single small cohort and has not been established in large breast cancer studies, so treat it as preliminary.
• Lung cancer: in a Chinese case-control study, the CC genotype at rs2151280 was linked to about 36% lower overall lung cancer odds. The adenocarcinoma signal was lower as well.
• Childhood low-grade glioma: rs573687 raised astrocytoma risk by about 27% across six ancestry groups. The signal was absent in high-grade tumors, so the biology is not the same across all gliomas.

Metabolic Syndrome And Lifespan

The CC genotype at rs1333045 was linked to 44% lower odds of metabolic syndrome and to higher HDL in one study. A study of 2,304 extreme-longevity cases found a 9p21 variant near genome-wide significance, and a million-parent lifespan analysis also validated a signal near CDKN2B-AS1.

The lifespan link probably runs partly through cardiovascular disease. In the million-parent analysis, cardiovascular disease variants explained a large share of the genetic signal for lifespan. Avoiding an early heart attack is one of the more direct ways genes can change the odds of reaching old age.

Why One Variant Points In Opposite Directions

9p21 can point in opposite directions because the report may be talking about different SNPs. One SNP can raise coronary risk. Another can lower lung cancer odds. A third can matter more for glaucoma. This is why a 9p21 result has to be read by variant name.

The shared theme is cell-growth control. Arteries, optic nerves, pancreatic tissue, and tumors use those growth brakes differently. So a variant that changes one tissue's response may have a different effect in another.

Ancestry Matters More Than Usual Here

Most of the evidence at 9p21 comes from European and East Asian populations. The Saudi replication added evidence in an Arab population. African-ancestry populations show weaker or different associations with many of the same variants, because the variants are not equally common and don't travel with the same neighboring DNA in every ancestry.

If your ancestry is not well represented in the studies behind a given variant, the risk estimate should be treated as less certain than it looks.

What A Positive Result Can Change

Genotype results are permanent. There is no retesting, no reversal, no supplement that will change what your DNA says. What changes is what you do about the risks the result exposes.

If your report includes a coronary-risk SNP, check ApoB and Lp(a), track blood pressure, and consider coronary artery calcium scoring earlier than age-based screening would suggest. If it includes a glaucoma-risk SNP, use optic nerve imaging and visual field testing on a regular schedule, even if your eye pressure looks normal. If it includes a pancreatic or breast cancer SNP, use it as one input among many. Family history matters more, and a common 9p21 variant by itself does not warrant imaging surveillance.

What A Negative Result Does Not Mean

Not carrying a risk variant at 9p21 does not mean you are safe from heart disease, glaucoma, or cancer. This region is one of hundreds of common genetic contributors to those risks, and none of them dominate.

The strongest 9p21 heart disease variants shift odds by roughly 20 to 30% per risk allele, and about 25% comparing two versus one at-risk allele in pooled analyses. That matters across a population. It is still smaller than what ApoB, blood pressure, and smoking do to your risk over decades. Standard prevention still counts if this test comes back reassuring.

Where This Test Falls Short

No study has shown that giving asymptomatic people a 9p21 result detects disease earlier or prevents events. The EGAPP evidence review found the 9p21 heart signal had strong credibility, with odds ratios near 0.80 and 1.25 comparing zero or two versus one at-risk allele, but reclassification of risk was small and no study demonstrated improved health outcomes. The 2010 ACCF/AHA guideline reached the same conclusion: a 9p21 SNP did not meaningfully improve risk discrimination beyond a global risk score such as Reynolds. That is the hard limit. The result can sharpen a prevention plan, but it can't replace the measurements that show current risk.

When Results Can Mislead

Most errors come from treating a narrow genetic result as broader than it is. A negative 9p21 result only rules out the exact variants tested. A direct-to-consumer raw-data call is not the same as a clinical-grade result. An ancestry mismatch can make a risk estimate look more precise than it is.

A variant of uncertain significance is a DNA change the lab can't yet interpret. It should not drive screening by itself. If a result conflicts with family history, or if the sample came from blood after a stem-cell transplant or during a blood cancer workup, confirm it with a clinical lab using a different method or sample type.

What To Do With The Result

Start by matching the variant name on the report to the disease evidence behind it. If the result is unexpected, high stakes, or from direct-to-consumer data, confirm it once. Don't repeat it to track progress.

Then decide what to measure more closely. For coronary risk: ApoB, Lp(a), blood pressure, and calcium score. For glaucoma: optic nerve imaging and visual fields. For cancer: family history and standard screening rules, with a genetic counselor if several relatives have the same cancer or the panel returns a variant of uncertain significance. Share the named variant, not just "9p21 positive," with adult siblings, parents, and children when they are old enough to use it.